CTI BioPharma

Biotechnology ResearchWashington, United States51-200 Employees

CTI BioPharma is now part of a merged biopharma company formed with Sobi AB, focused on developing and delivering medicines for rare and debilitating diseases. Based in Seattle, Washington, the organization combines resources from both entities to pursue therapies for conditions with limited treatment options. It operates within the biotechnology research industry and concentrates on rare-disease drug development. Its primary customers are patients affected by these conditions, as well as the clinicians and health systems that treat them. 

A recent development involves public scientific engagement, such as presenting new clinical and real-world data at the EHA 2026 conference. The merged entity continues to advance its research and clinical efforts within the rare-disease space.

Sign up for free to view info

Email Format Employee directory